|
|
|
|
|
|
|
CUSIP No. 03890D108
|
|
SCHEDULE 13D
|
|
Page
3
of 5 Pages
|
Item 1. Security and Issuer
This Amendment No. 1 (“Amendment No. 1”) amends the Schedule 13D, dated October 12, 2018, filed by Raymond Tabibiazar,
M.D., relating to shares of common stock, par value $0.0001 per share, of Aravive, Inc. (formerly known as Versartis, Inc.), a Delaware corporation (the “Issuer”). The Issuer’s principal executive office is located at River Oaks
Tower, 3730 Kirby Drive, Suite 1200, Houston, Texas 77098.
Item 2. Identity and Background
(a) The name of the reporting person is Raymond Tabibiazar, M.D. (the “Reporting Person”).
(b) The business address of the Reporting Person is 245 First Street, 18th floor, Cambridge, Massachusetts 02142.
(c) The principal occupation of the Reporting Person is Managing Director of 526 Ventures and Chairman and Chief Executive Officer of a Boston
based biotechnology company. The Reporting Person ceased to serve as a director of the Issuer on December 31, 2020.
(d) During the
last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the last five years, the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result was not or is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to
such laws.
(f) The Reporting Person is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 is hereby amended and supplemented as follows:
On January 3, 2019, Dr. Tabibiazar was issued (a) an option to purchase 7,500 shares of Common Stock that vest (i) 625
shares of Common Stock vested immediately upon grant and (ii) the balance vest pro rata on a monthly basis over the next 33 months commencing on February 12, 2019 and (b) an option to purchase 4,688 shares of Common Stock that vest
(i) 1,563 shares of Common Stock vested immediately upon grant and (ii) 625 vested on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Issuer’s
next annual meeting of stockholders and are now fully vested as of the date hereof.
On September 12, 2019, Dr. Tabibiazar was
issued an option to purchase 7,500 shares of Common Stock all of which vest pro rata on a monthly basis commencing on October 12, 2019 with full vesting, if not fully vested by October 12, 2020, on the date of the Issuer’s 2020 annual
meeting of stockholders. The options are fully vested.
On September 14, 2020, Dr. Tabibiazar was issued an option to purchase
16,029 shares of Common Stock all of which vest pro rata on a monthly basis commencing on October 14, 2020 with full vesting, if not fully vested by October 14, 2021, on the date of the Issuer’s 2021 annual meeting of stockholders.
From April 5, 2021 through April 12, 2021, Dr. Tabibiazar exercised options to purchase an aggregate of 58,406 shares of
Common Stock that were scheduled to expire on April 26, 2021 and pursuant to a Rule10b5-1 plan that the Reporting Person entered into in December 2020 sold the shares that he received upon exercise of
such options. The exercise price of the options was $0.06 per share.
Item 4. Purpose of Transaction
The disclosure provided in Item 3 above is incorporated herein by reference.
Item 5. Interest in Securities of the Issuer
(a)
See rows (11) and (13) of the cover pages to this Amendment No. 1 to Schedule 13D for the aggregate number and percentages of the Common Stock beneficially owned by the Reporting Person. The percentages used in this Amendment No. 1 to
Schedule 13D are calculated as described in footnote 1 to the cover pages to this Amendment No. 1 Schedule 13D.